Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BPC 15; BPC-157; PCO-02; PL 10; PLD 116; PLD 14736

Latest Information Update: 28 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Zagreb
  • Developer PharmaCotherapia; PLIVA d.d.
  • Class Anti-inflammatories; Antiallergics; Antiulcers; Cytoprotectives; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ulcerative colitis

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in Mexico (PO, Tablet)
  • 01 Oct 2015 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Mexico (PO) (NCT02637284)
  • 01 Jun 2005 Data presented at Digestive Disease Week-2005 (DDW-2005) have been added to the adverse events and Inflammatory bowel disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top